Pharmacists often give nod on meds: survey

Share this article:
Pharmacists often give nod on meds: survey
Pharmacists often give nod on meds: survey

Pharmacists, recent data suggest, may be influencing patients' drug decisions to the tune of nearly seven over-the-counter products and five prescription drugs, on average, per day. Findings imply that these HCPs remain a crucial, and accessible, touchpoint for patients and marketers alike.

Kantar Media's 2013 Pharmacy Readership study surveyed more than 130,000 US pharmacists. Of those, 39% of full-time pharmacists were retail staff and 30% were retail managers; 9% of those polled overall were also members of formulary committees.

On average, they made 4.8 prescription recommendations and seven OTC recommendations per day. Those numbers were slightly elevated from last year's results, which found 4.5 recommendations for prescriptions and 6.7 for OTC.

However, for a group that is filling 265 prescriptions on average per day, the potential to influence up to five prescribing decisions is a drop in the bucket. 

Kantar also found that the conversation starting, "Which do you recommend?" is a common one. Of the pharmacists polled, 52% of their customers requested a drug substitution and, somewhat unsurprisingly, pharmacists are recommending a generic drug 85% of the time over a branded drug (when they have the option to do so).

While pharmacists may be pushing generics over branded, they have signaled a willingness to listen to pharma. Fifty seven percent said their policy toward sales representatives is to see “all or most” of them.

They're also engaging more on smartphones and tablets during the work day. The results showed a 2% jump in smartphone usage (pictured) from year-to-year while at work, and a 7% jump in tablet usage, as well.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...